Author(s):
Sampada S. Bhosale, S. Sivakkumar, Arulmozhi S.
Email(s):
arulmozhi.s@bharatividyapeeth.edu
DOI:
10.52711/0974-360X.2025.00426 
Address:
Sampada S. Bhosale1,2, S. Sivakkumar3, Arulmozhi S.2*
1Department of Pharmacology, Bharati Vidyapeeth’s College of Pharmacy, CBD Belapur, Navi Mumbai - 400614, Maharashtra.
2Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune - 411038, Maharashtra.
3Department of Gunapadam, National Institute of Siddha, Chennai - 600047, Tamil Nadu.
*Corresponding Author
Published In:
Volume - 18,
Issue - 7,
Year - 2025
ABSTRACT:
Herbal drugs are often perceived as safe, effective and of good quality. However, the increased utilisation of herbal drugs has raised concerns about adverse effects and suspected toxicity. Therefore, conducting comprehensive safety studies of herbal drugs and formulations and documenting them is of paramount importance. Siddha formulation, Bhiramiyadhi Bhavanai Choornam (BBC) is a mixture of 15 herbs in proportion according to the traditional formula and is reported to be used as a memory enhancer. However, it has not been through safety pharmacological studies. The current study used ICH 7A guidelines to provide safety pharmacological data of Bhiramiyadhi Bhavanai Choornam. For 28 days, the rats were orally administered doses of 215, 430, and 860 mg/kg/day of BBC. The impact on the central nervous system (CNS) was evaluated using a modified Irwin’s test. The cardiovascular system was assessed by analysing electrocardiogram (ECG), heart rate fluctuations, and measuring changes in blood pressure. Respiratory parameters, including respiratory rate, tidal volume, and minute respiratory volume, were measured using a whole-body plethysmograph. The results of these studies indicated increased grooming, vocalisation, aggressiveness, chromodacryrrohea and a decrease in faecal consistency indicating BBC may have CNS stimulant and parasympathetic effects. There was no significant change observed in cardiovascular and respiratory parameters. Based on these findings, it can be concluded that BBC is a safe herbal formulation that does not have substantial untoward effects on the CNS, respiratory and cardiovascular systems.
Cite this article:
Sampada S. Bhosale, S. Sivakkumar, Arulmozhi S.. Safety Pharmacology Evaluation of Herbal Formulation: A Preclinical Core Battery Approach in Alignment with ICH Guidelines. Research Journal of Pharmacy and Technology. 2025;18(7): 2971-9. doi: 10.52711/0974-360X.2025.00426
Cite(Electronic):
Sampada S. Bhosale, S. Sivakkumar, Arulmozhi S.. Safety Pharmacology Evaluation of Herbal Formulation: A Preclinical Core Battery Approach in Alignment with ICH Guidelines. Research Journal of Pharmacy and Technology. 2025;18(7): 2971-9. doi: 10.52711/0974-360X.2025.00426 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-7-6
REFERENCES:
1. ICH Harmonized Tripartite Guideline, S7A Safety Pharmacology Studies for Human Pharmaceuticals (2001). US Department of Health and Human Services, FDA; http://www.fda.gov/cder/guidance/P266_27807
2. Pugsley MK, Authier S, Curtis M. Principles of Safety Pharmacology. British Journal of Pharmacology. 2008; July 7; 154: 1382–1399. doi:https://doi.org/10.1038/bjp.2008.280
3. Hamdam J, Sethu S, Smith T, et al. Safety pharmacology — Current and emerging concepts. Toxicology and Applied Pharmacology. 2013. Dec 1; 273(2): 229–41. doi:https://doi.org/10.1016/j.taap.2013.04.039
4. Bass AS, Kinter L, Williams P.Origins, practices and future of safety pharmacology. Journal of Pharmacological and Toxicological Methods. 2004; May 6; 49(3): 145–151. doi: https://doi.org/10.1016/j.vascn.2004.02.007
5. Bass AS, Vargas HM, Kinter LB. Introduction to Nonclinical Safety Pharmacology and the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods. 2004; May 6; 49(3): 141–144.doi: https://doi.org/10.1016/j.vascn.2004.02.004
6. WHO Global Centre for Traditional Medicine. 2022 India Brand Equity Foundation. doi https://www.ibef.org/blogs/who-global-centre-for-traditional-medicine-gctm.
7. Pferschy-Wenzig EM, Bauer R. The relevance of pharmacognosy in pharmacological research on herbal medicinal products. Epilepsy and behaviour. 2015; Jul 10; 52: 344–362. doi: https://doi.org/10.1016/j.yebeh.2015.05.037
8. Shaw D, Graeme L, Pierre D, et al.Pharmacovigilance of herbal medicine. Journal of Ethnopharmacology. 2012; Apr 12; 140(3): 513–518. doi: https://doi.org/10.1016/j.jep.2012.01.051
9. R Meena, G Kiruthiga, P Prakash. Evaluation of Siddha Compound Formulation Mahathoothulai chooranam in Combating Respiratory Illness: A Narrative Review. Research Journal of Pharmacy and Technology. 2023April; 16(4): 2057-2060. doi: 10.52711/0974-360X.2023.00338
10. P Mohamed Abdulla Saibhu.Kaduukkai Vallaraiyin Thani Maanbu. Directorate of Indian Medicine and Homeopathy. 1992.
11. Bhosale SS,. Bhos Sivakumar S, Jamadagni S, Arulmozhi S. Therapeutic potential of Bhiramiyadhi bhavanai choornam in ameliorating scopolamine-induced impaired learning and memory in rats: neuroprotective effects and mechanistic insights. Research Journal of Pharmacy and Technology. 2024; Feb; 17(2): 553-562. doi: 10.52711/0974-360X.2024.00086
12. Moscardo E, Maurin A, Dorigatti R, et al. An optimised methodology for the neurobehavioural assessment in rodents. Journal of Pharmacological and Toxicological Methods. 2007; Oct 31; 56(2); 239–255. doi: https://doi.org/10.1016/j.vascn.2007.03.007
13. Creason JP. Data Evaluation and Statistical Analysis of Functional Observational Battery Data Using a Linear Models Approach.Journal of the American College of Toxicology. 1989 Nov1; 8(1): 157–169. doi: https://doi.org/10.3109/10915818909009102
14. Mathiasen JR, Moser VC. The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents. Current Protocols in Pharmacology. 2018; Sep 4; 83(1): 1-18. doi: https://doi.org/10.1002/cpph.43
15. Ghule AE, Kulkarni CP, Bodhankar SL, et al . Effect of pretreatment with coenzyme Q 10 on isoproterenol-induced cardiotoxicity and cardiac hypertrophy in rats. Current Therapeutic Research. 2009; Dec; 70: 460-71. doi:https://doi.org/10.1016/j.curtheres.2009.12.004.
16. Moss AJ. The QT interval and torsade de pointes. Drug safety. 1999; Dec; 21(1): 5–10. doi: https://doi.org/10.2165/00002018-199921001-00002
17. Mali VR, Mohan V, Bodhankar SL. Antihypertensive and cardioprotective effects of the Lagenaria siceraria fruit in NG-nitro-L-arginine methyl ester (L-NAME) induced hypertensive rats. Pharmaceutical Biology. 2012; Sep 21; 50(11): 1428–1435. doi: https://doi.org/10.3109/13880209.2012.684064
18. Satone BD.Deshmukh AA, Undale VR. Preclinical Evaluation of Antihypertensive Activity of Combination of Herbs Extract in Wistar Rats. Research J. Pharm. and Tech. May 2020; 13(5): 2069-2075. https://doi.org/10.5958/0974-360X.2020.00372.8
19. DeLorme MP, Moss OR.Pulmonary function assessment by whole-body plethysmography in restrained versus unrestrained mice. Journal of Pharmacological and Toxicological Methods. 2002; Feb; 47(1): 1–10. doi: https://doi.org/10.1016/s1056-8719(02)00191-0
20. Coggins CRE, Duchosal F, Musy, C, et al. Measurement of respiratory patterns in rodents using whole-body plethysmography and a pneumotachograph. Laboratory Animals. 1981; Apr; 15(2): 137–140. doi: https://doi.org/10.1258/002367781780959125
21. Sanghi DK, Tiwle R. Herbal Drugs an Emerging Tool for Novel Drug Delivery Systems. Research Journal of Pharmacy and Technology. 2013; Sep; 6(9): 962-966.
22. Islam M, Ramanjaneyulu. J, Veeresh Babu, Hoque M, Narayana Swamy V.B. Studies on Memory Enhancing Property of Bravobol- A Polyherbal Formulation in Experimentally Induced Alzheimers Disease in Experimental Animals. Asian Journal of Research in Pharmaceutical Sciences. 2015; 5(2): 1-8.
23. Islam M, Ramanjaneyulu. J, Veeresh Babu, Hoque M, Narayana Swamy V.B . Studies on Memory Enhancing Property of Sumenta-A Polyherbal Formulation in Experimentally Induced Alzheimer Disease in Experimental Animals. Research Journal of Pharmacology and Pharmacodynamics. 2015; June; 7(2): 61-67. doi: https://doi.org/10.5958/2321-5836.2015.00013.0
24. Shrivastava A, Jain R, Agrawal RK, Ahirwar D. Clinical Trial of Herbal Drugs and Products in India: Past and Current Status and Critical Issues. Research Journal of Pharmacy and Technology. 2008; June; 1(2): 69-74.
25. Kalantri MR , Aher AN. Review on herbal drugs used in treatment for Asthma. Research Journal of Pharmacognosy and Phytochemistry. 2018; March; 10(1): 63-67.
26. Chavhan AB, Bhoi DM. Pharmacovigilance: Drug Safety Monitoring. Asian Journal of Pharmacy and Technology. 2019; March; 9(1): 49-52. doi: https://doi.org/10.5958/2231-5713.2019.00009.6
27. Mansoori A, Gautam R, Rathore K. Safety Pharmacology: An Overview. International Journal of Applied Pharmaceutical and Biological Research. 2016; 1(1): 90-98.
28. Zhou XR, Rong Q, Xu M, et al. Safety pharmacology and subchronic toxicity of jinxing granules in rats. BMC Veterinary Research. 2017; Jun 17; 13(1): 1-11. doi: https://doi.org/10.1186%2Fs12917-017-1095-3
29. Redfern WS, Strang I, Storey S, et al. The spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds.Journal of Pharmacological and Toxicological Methods. 2005; Jun; 52(1): 77–82. doi: https://doi.org/10.1016/j.vascn.2005.04.005
30. Ramos A, Berton O, Mormède P, et al. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behavioural Brain Research. 1997; Apr; 85(1): 57–69. doi: https://doi.org/10.1016/s0166-4328(96)00164-7
31. Kim M, Chung H, Jun M. ECG Biomarker-based Heart Disease Automation Detection Scheme.May 2019; 12(5): 2267-2270. https://doi.org/10.5958/0974-360X.2019.00377.9
32. Redfern W, Carlsson L, Davis A et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research. 2003 Apr 1; 58(1): 32–45. doi: https://doi.org/10.1016/s0008-6363(02)00846-5
33. Malik M, Camm AJ. Evaluation of Drug-Induced QT Interval Prolongation. Drug Safety. Apr 2001; 24(5): 323–351. doi:https://doi.org/10.2165/00002018-200124050-00001
34. Gras J, Llenas J, Palacios JM. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea pig model of arrhythmogenicity. British Journal of Pharmacology. 1996; Sep; 119(2): 187–188. doi: https://doi.org/10.1111/j.1476-5381.1996.tb15968.x
35. Reinmann B, Stocks J, Frey U. Assessment of an infant whole-body plethysmograph using an infant lung function model. European Respiratory Journal. 2001; 17(4): 765–772. doi: https://doi.org/10.1183/09031936.01.17407650
36. Bargeton D, Barres G. Time characteristics and frequency response of body plethysmograph. Progress in Respiratory Research. 1969; 4: 2-23. doi: https://doi.org/10.1159/000386230
37. Dolhnikoff M, Mauad T, Ludwig, MS1. Extracellular Matrix and Oscillatory Mechanics of Rat Lung Parenchyma in Bleomycin-induced Fibrosis. American Journal of Respiratory and Critical Care Medicine. 1999; November; 160(5): 1750–1757. doi: https://doi.org/10.1164/ajrccm.160.5.9812040
38. McHugh NA, Miyamoto M, Kelly CM, et al. Evaluation of Respiratory Pharmacology in the Conscious Rat using Whole Body Bias Flow Plethysmography.The FASEB Journal. 2006; Mar; 20(4): A674-b. doi: https://doi.org/10.1096/fasebj.20.4.A674-b